These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973 [TBL] [Abstract][Full Text] [Related]
7. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. Sundriyal S; Bharatam PV Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404 [TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. Pirard B J Comput Aided Mol Des; 2003 Nov; 17(11):785-96. PubMed ID: 15072437 [TBL] [Abstract][Full Text] [Related]
9. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. Gani OA; Sylte I J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851 [TBL] [Abstract][Full Text] [Related]
10. A novel strategy for designing the selective PPAR agonist by the "sum of activity" model. Huang HJ; Lee KJ; Yu HW; Chen HY; Tsai FJ; Chen CY J Biomol Struct Dyn; 2010 Oct; 28(2):187-200. PubMed ID: 20645652 [TBL] [Abstract][Full Text] [Related]
11. The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands. Subramani PA; Reddy MC; Narala VR Endocr Metab Immune Disord Drug Targets; 2013 Jun; 13(2):175-83. PubMed ID: 23713695 [TBL] [Abstract][Full Text] [Related]
13. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Mirza AZ; Althagafi II; Shamshad H Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829 [TBL] [Abstract][Full Text] [Related]
14. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. Hong F; Xu P; Zhai Y Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458 [TBL] [Abstract][Full Text] [Related]
15. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. Derosa G; Sahebkar A; Maffioli P J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353 [TBL] [Abstract][Full Text] [Related]
17. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Feldman PL; Lambert MH; Henke BR Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282 [TBL] [Abstract][Full Text] [Related]
19. [Development of a cell-based peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of triterpenoids isolate from Alismatis Rhizoma]. Li XY; Wang XH; Huang XQ; Wu TT; Xu W; Wu SS Zhongguo Zhong Yao Za Zhi; 2016 Nov; 41(21):4015-4022. PubMed ID: 28929690 [TBL] [Abstract][Full Text] [Related]
20. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Tenenbaum A; Motro M; Fisman EZ Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]